These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 29659569)

  • 1. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
    PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
    Kote-Jarai Z; Jugurnauth S; Mulholland S; Leongamornlert DA; Guy M; Edwards S; Tymrakiewitcz M; O'Brien L; Hall A; Wilkinson R; Al Olama AA; Morrison J; Muir K; Neal D; Donovan J; Hamdy F; Easton DF; Eeles R; ;
    Br J Cancer; 2009 Jan; 100(2):426-30. PubMed ID: 19127258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
    Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
    Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
    Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
    Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
    Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
    Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
    Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
    Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
    Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
    J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
    Beebe-Dimmer JL; Zuhlke KA; Johnson AM; Liesman D; Cooney KA
    Prostate; 2018 Apr; 78(5):321-326. PubMed ID: 29356034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.